Squarepoint Ops LLC Makes New $326,000 Investment in Xencor, Inc. (NASDAQ:XNCR)

Squarepoint Ops LLC purchased a new position in Xencor, Inc. (NASDAQ:XNCR) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 17,230 shares of the biopharmaceutical company’s stock, valued at approximately $326,000.

Several other large investors also recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in shares of Xencor by 153.7% during the first quarter. GAMMA Investing LLC now owns 2,172 shares of the biopharmaceutical company’s stock worth $48,000 after buying an additional 1,316 shares in the last quarter. SG Americas Securities LLC acquired a new position in Xencor during the second quarter valued at approximately $154,000. XTX Topco Ltd acquired a new position in Xencor during the second quarter valued at approximately $196,000. Acadian Asset Management LLC acquired a new position in Xencor during the first quarter valued at approximately $206,000. Finally, Los Angeles Capital Management LLC acquired a new position in Xencor during the first quarter valued at approximately $229,000.

Wall Street Analysts Forecast Growth

XNCR has been the subject of a number of recent analyst reports. Wedbush reaffirmed an “outperform” rating and issued a $34.00 price objective on shares of Xencor in a research report on Monday, September 9th. BMO Capital Markets reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Xencor in a research report on Tuesday, August 6th. JPMorgan Chase & Co. cut their price objective on Xencor from $30.00 to $27.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Raymond James cut their price objective on Xencor from $58.00 to $40.00 and set a “strong-buy” rating for the company in a research report on Friday, June 14th. Finally, Royal Bank of Canada raised their price objective on Xencor from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Thursday, September 26th. Two investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Xencor has an average rating of “Moderate Buy” and an average price target of $34.78.

Xencor Stock Performance

Shares of Xencor stock opened at $21.29 on Friday. Xencor, Inc. has a one year low of $15.31 and a one year high of $26.84. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -7.37 and a beta of 0.67. The business has a 50-day simple moving average of $18.53 and a 200 day simple moving average of $20.14. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.92 and a quick ratio of 6.92.

Xencor (NASDAQ:XNCR) last issued its earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.25). The firm had revenue of $16.96 million during the quarter, compared to the consensus estimate of $21.13 million. Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The business’s quarterly revenue was down 62.7% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.37) earnings per share. On average, research analysts anticipate that Xencor, Inc. will post -4.15 earnings per share for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.